Treace Medical Concepts, Inc. (NASDAQ:TMCI) Holdings Lifted by Fox Run Management L.L.C.

Fox Run Management L.L.C. increased its holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 54.0% in the 4th quarter, Holdings Channel reports. The fund owned 20,073 shares of the company’s stock after purchasing an additional 7,040 shares during the period. Fox Run Management L.L.C.’s holdings in Treace Medical Concepts were worth $149,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TMCI. Quarry LP purchased a new stake in shares of Treace Medical Concepts in the third quarter worth approximately $38,000. Quantbot Technologies LP acquired a new position in Treace Medical Concepts in the 4th quarter valued at approximately $69,000. HighTower Advisors LLC purchased a new stake in Treace Medical Concepts in the 3rd quarter worth approximately $58,000. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Treace Medical Concepts by 243.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,613 shares of the company’s stock valued at $62,000 after buying an additional 7,522 shares during the period. Finally, AlphaQuest LLC purchased a new position in shares of Treace Medical Concepts during the 4th quarter valued at $91,000. 84.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Treace Medical Concepts news, insider Sean F. Scanlan sold 50,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $7.97, for a total transaction of $398,500.00. Following the completion of the sale, the insider now directly owns 364,081 shares in the company, valued at $2,901,725.57. This represents a 12.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 24.43% of the company’s stock.

Analyst Ratings Changes

TMCI has been the subject of a number of recent research reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $8.00 price target on shares of Treace Medical Concepts in a research note on Tuesday, December 17th. Truist Financial reduced their target price on shares of Treace Medical Concepts from $10.00 to $9.50 and set a “hold” rating for the company in a research note on Thursday, March 13th. BTIG Research upgraded shares of Treace Medical Concepts from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Tuesday, February 4th. Finally, Lake Street Capital started coverage on shares of Treace Medical Concepts in a research note on Tuesday, December 31st. They issued a “buy” rating and a $14.50 price objective for the company. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.14.

Treace Medical Concepts Trading Up 1.0 %

NASDAQ:TMCI opened at $8.45 on Friday. The company has a quick ratio of 2.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.51. The company’s 50 day moving average is $9.24 and its 200-day moving average is $7.56. The firm has a market cap of $529.13 million, a price-to-earnings ratio of -8.54 and a beta of 0.77. Treace Medical Concepts, Inc. has a 12 month low of $3.92 and a 12 month high of $13.24.

About Treace Medical Concepts

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.